NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CRNX

*Your capital is at risk

$33.09

+0.480 (+1.47%)

At Close: Jun 03, 2026

Crinetics Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -30.35. In total, the insiders bought 2.19M and sold 1.45M CRNX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-30.35
● Buy	2.19M shares
● Sell	1.45M shares
64% Buy Activity Moderate Negative Correlation
Sell Signal Medium Confidence Apr 08, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -30.35. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 12, 2026 Sell	Common Stock S-Sale	Vivaldi Coelho Rogerio Director	Director	523 Value: $19.2K
Mar 03, 2026 Sell	Common Stock S-Sale	Schilke Tobin Chief Financial Officer	C-Suite Officer	6 713 Value: $266.3K
Mar 03, 2026 Sell	Common Stock S-Sale	Okey Stephanie Director	Director	3 000 Value: $119.0K
Feb 23, 2026 Buy	Common Stock A-Award	Kalofonos Isabel Chief Commercial Officer	Officer	34 000 Value: $1.49M
Feb 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Kalofonos Isabel Chief Commercial Officer	Officer	55 000 Value: $2.41M
Feb 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Betz Stephen F. Chief Scientific Officer	Officer	47 000 Value: $2.06M
Feb 23, 2026 Buy	Common Stock A-Award	Struthers Richard Scott President & CEO	CEO / President	62 000 Value: $2.71M
Feb 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Struthers Richard Scott President & CEO	CEO / President	228 000 Value: $9.98M
Feb 23, 2026 Buy	Common Stock A-Award	Schilke Tobin Chief Financial Officer	C-Suite Officer	32 000 Value: $1.40M
Feb 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Schilke Tobin Chief Financial Officer	C-Suite Officer	50 000 Value: $2.19M
Feb 23, 2026 Buy	Common Stock A-Award	Knight Jeff E. Chief Operating Officer	C-Suite Officer	34 000 Value: $1.49M
Feb 23, 2026 Buy	Stock Option (Right to Buy) A-Award	Knight Jeff E. Chief Operating Officer	C-Suite Officer	55 000 Value: $2.41M
Feb 23, 2026 Buy	Common Stock A-Award	Betz Stephen F. Chief Scientific Officer	Officer	30 000 Value: $1.31M
Jan 05, 2026 Buy	Common Stock M-Exempt	Kalofonos Isabel Chief Commercial Officer	Officer	2 500 Value: $101.5K
Jan 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Kalofonos Isabel Chief Commercial Officer	Officer	2 500 Value: $101.5K
Jan 05, 2026 Sell	Common Stock S-Sale	Kalofonos Isabel Chief Commercial Officer	Officer	2 500 Value: $137.5K
Dec 26, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Betz Stephen F. Chief Scientific Officer	Officer	18 000 Value: $34.4K
Dec 26, 2025 Buy	Common Stock M-Exempt	Betz Stephen F. Chief Scientific Officer	Officer	18 000 Value: $34.4K
Dec 18, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Struthers Richard Scott President & CEO	CEO / President	16 342 Value: $151.7K
Dec 18, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Struthers Richard Scott President & CEO	CEO / President	28 400 Value: $434.2K
Dec 18, 2025 Buy	Common Stock M-Exempt	Struthers Richard Scott President & CEO	CEO / President	28 400 Value: $434.2K
Dec 18, 2025 Buy	Common Stock M-Exempt	Struthers Richard Scott President & CEO	CEO / President	16 342 Value: $151.7K
Dec 01, 2025 Sell	Common Stock S-Sale	Pizzuti Dana Chief Med And Dev Officer	Officer	5 000 Value: $225.1K
Dec 01, 2025 Buy	Common Stock M-Exempt	Pizzuti Dana Chief Med And Dev Officer	Officer	5 000 Value: $84.5K
Dec 01, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Pizzuti Dana Chief Med And Dev Officer	Officer	5 000 Value: $84.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CRINETICS PHARMACEUTICALS INC

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c...

Read Full Profile Here